

[全部](#)[图片](#)[新闻](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 184,000 条结果（用时 0.63 秒）

您是不是要找：[Development of therapeutic options on type 2 diabetes in years: **GLP 1** agonists role in treatment; from past to future](#)

[The evolving world of GLP-1 agonist therapies for type 2 diabetes](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475287/> - [翻译此页](#)

作者：KCR Baynes - 2010 - 被引用次数：3 - [相关文章](#)

Keywords: exenatide, **GLP-1**, liraglutide, taspoglutide, **type 2 diabetes** mellitus, obesity ... **treatments** available for **treatment** of **type 2 diabetes** mellitus over the **last few** ... Early drug-development efforts were directed at **developing GLP-1 agonist** **Future** uses of **GLP-1 agonist therapies** include combination with insulin(s).

[Treatment approach to type 2 diabetes: Past, present and future](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304295/> - [翻译此页](#)

作者：K Blaslov - 2018 - [相关文章](#)

跳到LONGITUDINAL HISTORY OF **TREATMENT OPTIONS** IN **TYPE 2 DM** - This was the **year** when a Boston scientist ... The pharmacological **treatment options** in **type 2 DM**, ... of their **development** resulted in a ... **function** to achieve the effect[73,74]. ... **diabetes therapy**[67]. ... A second **GLP-1** receptor **agonist**, ...

[Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes ...](#)

spectrum.diabetesjournals.org/content/30/3/202 - [翻译此页](#)

作者：D Hinnen - 2017 - 被引用次数：5 - [相关文章](#)

Clinical Effects of **GLP-1** Receptor **Agonists** in **Type 2 Diabetes** **agonists** are in progress, and results are anticipated in the near **future**. ... If initiating **GLP-1** receptor **agonist therapy** early in the course of **treatment**, after The potential **role** of glucagon-like peptide 1 in diabetes. [Privacy policy](#) · [Google Analytics settings](#).

Name of Journal: *World Journal of Diabetes*

Manuscript NO: 47732

Manuscript Type: MINIREVIEWS

Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role in treatment; from the past to future

Dogruel H *et al.* Incretin-based therapy on T2DM

Hakan Dogruel, Mustafa Kemal Balci

Abstract

Diabetes mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia.

Type 2 diabetes (T2DM) accounting for 90% of cases globally. The worldwide

Match Overview

Match Number	Source	Words	Percentage
1	Internet crawled on 10-Dec-2017 www.soc-bdr.org	28	1%
2	Crossref Matthew H. Secrest, Jacob A. Udell, Kristian B. Filion. "The cardiovascular safety trials of DPP-4 inhibitors, GLP-..."	20	1%
3	Internet crawled on 28-Oct-2011 childrenwithdiabetes.com	15	1%
4	Internet crawled on 15-Apr-2019 academic.oup.com	15	1%
5	Internet crawled on 02-Jun-2019 epdf.pub	15	1%
6	Internet crawled on 22-Jan-2015 www.hivclinic.ca	13	1%
7	Internet crawled on 20-Jul-2008 bentham.org	13	1%
8	Internet crawled on 20-Feb-2019 link.springer.com	12	1%
9	Internet crawled on 24-Feb-2019 www.ncbi.nlm.nih.gov	12	1%
10	Internet crawled on 25-Mar-2019 onlinelibrary.wiley.com	12	1%
11	Internet crawled on 09-Mar-2016 www.jns.dergisi.org	12	1%



All

Images

Videos

翻译成中文

关闭取词

20,000 Results

Any time ▾

Including results for [development of therapeutic options on type 2 diabetes in years glp 1 agonists role in treatment; from past to future.](#)

Do you want results only for Development of therapeutic options on type 2 diabetes in years: GLP1 agonists role in treatment; from past to future?

Glucagon-like peptide-1 receptor agonists in the treatment ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792029>

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future Sanjay Kalra , Manash P. Baruah , 1 Rakesh K. Sahay , 2 Ambika Gopalakrishnan Unnikrishnan , 3 Shweta Uppal , 4 and Omolara Adetunji 5

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138587>

Oct 15, 2014 - In recent years the treatment focus for type 2 diabetes has shifted to prevention by lifestyle change and to more aggressive reduction of blood sugars during the early stage of treatment. Weight reduction is an important goal for many people with type 2 diabetes. Bariatric surgery is no longer considered a last resort treatment.

Cited by: 13

Author: Gerald H Tomkin

Publish Year: 2014

Glucagon-like peptide-1 receptor agonists for type 2 ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/jdi.12911>

Aug 12, 2018 - Development of glucagon-like peptide-1 (GLP-1) receptor agonists as a treatment in the management of type 2 diabetes is an example of a rational drug design, which follows characteristic steps required for proper pharmacological development (Figure 1). The process has also engaged many players, in particular scientists, the research ...

Cited by: 1

Author: Bo Ahrén

Publish Year: 2019

Management of type 2 diabetes: new and future ...

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(11\)60207-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60207-9/fulltext)

Jun 25, 2011 - The increasing prevalence, variable pathogenesis, progressive natural history, and complications of type 2 diabetes emphasise the urgent need for new treatment strategies. Longacting (eg, once weekly) agonists of the glucagon-like-peptide-1 receptor are advanced in development, and

2,720 Results Any time ▾

Glucagon-like peptide-1 receptor agonists in the treatment ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792029>

Glucagon-like peptide-1 receptor agonists in the treatment of **type 2 diabetes**: Past, present, and future. ... the enormous progress in this field has paved the way for other **therapeutic options** for tailored management of patients with **type 2 diabetes**. ... Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once ...

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 ...

<https://spectrum.diabetesjournals.org/content/30/3/202>

The incretin system has become an important target in the treatment of **type 2 diabetes** in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with **type 2 diabetes** but may be augmented by administration of GLP-1 receptor ...

Glucagon-like peptide-1 receptor agonists for type 2 ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/jdi.12911>

Aug 12, 2018 · Today, **glucagon-like peptide-1 (GLP-1) receptor agonists** are established glucose-lowering drugs used in the management of **type 2 diabetes**. Their **development** emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is the key defect of hyperglycemia.

Cited by: 1 Author: Bo Ahrén

Publish Year: 2019

Glucagon-Like Peptide 1-Based Therapies for Type 2 ...

<https://clinical.diabetesjournals.org/content/23/2/56>

IN BRIEF Therapies based on the incretin hormone glucagon-like peptide 1 are novel treatment **options** for **type 2 diabetes** that act through a variety of complementary mechanisms. Exenatide, which will likely become the first application to reach the market, has shown promise in phase III trials in reducing hemoglobin A1c without causing significant hypoglycemia or weight gain.

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 ...

https://www.researchgate.net/publication/287995956_Glucagon-Like_Peptide-1_Receptor...

PDF | Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly being used for treatment for **type 2 diabetes** mellitus, but consideration of benefits and potential ...

GLP-1 receptor agonists for individualized treatment of ...

<https://www.nature.com/articles/nrendo.2012.140>


Sep 04, 2012 · In this Review, the possibilities for utilizing GLP-1 receptor agonists in individualized treatment for **type 2 diabetes** mellitus are discussed. The ...

Cited by: 787 Author: Juris J. Meier

Publish Year: 2012 Author: Juris J. Meier

Glucagon-like peptide-1 receptor

Protein



The glucagon-like peptide 1 receptor (GLP1R) is a human gene which resides on chromosome 6. The protein encoded by this gene is a member of the glucagon receptor family of G protein-coupled receptors.

 Wikipedia

Data from: Wikipedia

[Suggest an edit](#)